Researchers from the School of Chinese Medicine at Hong Kong Baptist University (HKBU) have successfully developed a novel aptamer for the treatment of osteogenesis imperfecta (OI) with the aid of artificial intelligence technology. This represents the first time that a drug developed in Hong Kong has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA).
What is OI?Also known as “brittle bone disease” it is a rare hereditary bone disease with no effective treatment to date. It affects 6 to 7 people per 100,000 worldwide. It is estimated that 700 to 800 people in Hong Kong have OI. It has been reported that inhibition of sclerostin, a protein that regulates bone formation, can improve the clinical presentation of OI reports QS WowNews.
The Research Team
The Hong Kong-based team included Professor Zhang Ge, Associate Director of HKBU’s Law Sau Fai Institute for Advancing Translational Medicine in Bone & Joint Diseases, and Professor Lyu Aiping, Director of HKBU’s Institute of Integrated Bioinformedicine and Translational Science—strategically screened and optimized a new class of molecule-nucleic acid aptamers against the sclerostin prote...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).